Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | 0 CommentsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.
Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.